Apr 16 |
IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
|
Apr 10 |
IN8bio gains after new preclinical data for nsCAR-T cell therapy platform
|
Apr 9 |
IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024
|
Mar 14 |
IN8bio GAAP EPS of -$0.22
|
Mar 14 |
IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights
|
Mar 5 |
IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024
|
Feb 26 |
IN8bio to Present at Upcoming Investor Conferences
|
Feb 14 |
IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology
|
Jan 12 |
IN8bio files to sell 42.7M shares for holders
|
Jan 4 |
In8bio stock jumps 11% following clinical update
|